[2][3][4] In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations.

[4] Mydecine made the first legal import of magic mushrooms into Canada in 2021.

[6][7] Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003),[8][9][10] MYCO-004 (a patch-delivered tryptamine),[11][12] and MYCO-005 (a novel aza psilocin analogue with putatively better safety)[13][14][2] and the novel MDMA-like entactogens MYCO-002 (putatively safer),[15][16] MYCO-006 (short-acting),[17][18][5][3] and MYCO-007 (short-acting).

[19][20][21][1] Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) as short-acting MDMA analogues.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub.